Virtual for Care Atrial Fibrillation Patients Using VIRTUES
Virtual for Care Atrial Fibrillation Patients Using VIRTUES (Virtual Integrated Reliable Transformative User-Driven E-Health System)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Rachel A Caris, BScN
- Phone Number: 32835 5196858500
- Email: rachel.caris@lhsc.on.ca
Study Locations
-
-
Nova Scotia
-
Halifax, Nova Scotia, Canada, B3H 2Y9
- Queen Elizabeth Ii Health Sciences Centre
-
Contact:
- Ratika Parkash, MD
- Phone Number: 902-473-2700
-
-
Ontario
-
London, Ontario, Canada, N6A 5A5
- Rachel Caris
-
Toronto, Ontario, Canada, M4N 3M5
- Sunnybrook Health Sciences Centre
-
Contact:
- Dana Murray, BScN
- Phone Number: 1994 416-480-6100
-
Principal Investigator:
- Benedict Glover, MD
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- able to provide informed consent
- documented symptomatic new-onset or pre-existing, non-valvular AF
- ER visit or hospitalization for primary AF in the last 6 months
- proficient in the English language
Exclusion Criteria:
- unable to provide informed consent
- planning to move/relocate during the period of study
- current pregnancy
- patient is a prisoner/incarcerated
- no access to a smart device with Bluetooth capabilities
- planned percutaneous coronary intervention, coronary artery bypass graphing or heart valve surgery within the next year
- any medical condition making 1 year survival unlikely
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: VIRTUES Arm
Patients in the VIRTUES arm will be offered enrollment into the virtual atrial fibrillation care platform.
|
VIRTUES is a digital health platform that offers 2 way communication between clinicians and patients to address symptoms stemming from atrial fibrillation.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of patients who present to the emergency department due to atrial fibrillation, after their index visit
Time Frame: 12 months
|
See title
|
12 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of AF-related ER visit per patient, post index visit
Time Frame: 12 months
|
See title
|
12 months
|
|
Utility of the system
Time Frame: 12 months
|
Number of uses of the system/patient, number of accesses to the health record, number of heart rhythm VIRTUES team - patient feedbacks on the VIRTUES app, percentage of care plans followed by the patient
|
12 months
|
|
Survey-based experience with the VIRTUES application
Time Frame: Baseline, 3 months, 12 months
|
Survey-based experience will be determined by the "Virtual AF Care Patient Satisfaction Questionnaire".
The questionnaire consists of 5 questions regarding the VIRTUES platform using a 5 point likert scale (strongly agree to strongly disagree) in addition to a final open ended question asking for feedback regarding the application.
|
Baseline, 3 months, 12 months
|
|
Pre and post patient reported outcomes using the Atrial Fibrillation Effect on Quality of Life (AFEQT) Questionnaire and the EQ-5D-5L
Time Frame: Baseline, 3 months, 12 months
|
The Atrial Fibrillation Effect on QualiTy-of-life (AFEQT) questionnaire is a well-validated questionnaire with 2 sections.
The first section asked about a patient's incidence of atrial fibrillation, the second section inquires as to the presence of atrial fibrillation symptomsand how limiting they were.
In general, higher scores mean more frequent atrial fibrillation symptoms that are very/extremely limiting and bothersome.
|
Baseline, 3 months, 12 months
|
|
Time to stroke/TIA, systematic embolism, cardiovascular (CV) hospitalization, death
Time Frame: 12 months
|
The length of time between index presentation for atrial fibrillation and the onset of any of the above conditions will be calculated for both the retrospective and prospective cohorts.
|
12 months
|
|
Frequency of stroke/TIA, systematic embolism, cardiovascular (CV) hospitalization, death
Time Frame: 12 months
|
The number of any of the above conditions occurring in both the retrospective and prospective cohorts will be counted and analyzed.
|
12 months
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Allan C Skanes, Md, Lawson Health Research Institute
Study record dates
Study Major Dates
Study Start (Anticipated)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 4411
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Atrial Fibrillation
-
NCT07298473RecruitingParoxysmal Atrial Fibrillation (PAF) | Persistent Atrial Fibrillation | Atrial Fibrillation (AF)
-
NCT07187115RecruitingAtrial Fibrillation (AF) | Persistant Atrial Fibrillation
-
NCT07601763RecruitingAtrial Fibrillation Ablation | Atrial Fibrillation (AF) | Radiofrequency Catheter Ablation | Atrial Fibrillation Recurrent | Pulsed Field Ablation
-
NCT06260670CompletedArrhythmias, Cardiac | Atrial Fibrillation, Persistent | Persistent Atrial Fibrillation | Longstanding Persistent Atrial Fibrillation
-
NCT07633509Not yet recruitingAtrial Fibrillation (AF) | Atrial Fibrillation Catheter Ablation
-
NCT07575828Not yet recruitingParoxysmal Atrial Fibrillation (PAF) | Persistent Atrial Fibrillation
-
NCT07446244Enrolling by invitationPersistent Atrial Fibrillation | Persistent Atrial Fibrillation Longstanding
-
NCT05883631Active, not recruitingAtrial Fibrillation | Arrhythmias, Cardiac | Arrhythmia | Atrial Flutter | Atrial Fibrillation, Persistent | Atrial Tachycardia | Atrial Arrhythmia | Atrial Fibrillation Paroxysmal | Atrial Fibrillation, Paroxysmal or Persistent
-
NCT03732794Active, not recruitingPersistent Atrial Fibrillation | Atrial Fibrillation (AF) | Longstanding Persistent Atrial Fibrillation
-
NCT07444320RecruitingParoxysmal Atrial Fibrillation | Persistent Atrial Fibrillation